DRKS00005974已完成未知
Randomized controlled clinical study for 3-D volumetric evaluation of two techniques for periimplant guided bone regeneration procedures - 3D GBR
niversität Zürich, Zentrum für Zahnmedizin, Klinik für Rekonstruktive Zahnmedizin0 个研究点目标入组 27 人开始时间: 2014年6月23日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 27
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled study
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •Patients in need of an implant therapy
- •- vertical dehiscence of 3mm or more
- •- good general health conditions
排除标准
- •Contraindications for implant therapy
研究者
相似试验
已完成
不适用
Clinical trial to evaluate 3D-printed denturesPreference for type of denturesOral HealthISRCTN17073439niversity of Leeds18
进行中（未招募）
1 期
Phase 3 Study of Pembrolizumab with and without Epacadostat as a second treatment after a platinum containing chemotherapy for recurring or metastatic bladder cancerRecurrent or Progressive Metastatic Urothelial Carcinoma in Patients who have Failed a First-Line Platinum-containing Chemotherapy Regimen for Advanced/Metastatic DiseaseMedDRA version: 20.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 100000004864EUCTR2017-002310-31-DKIncyte Biosciences Distribution B.V.85
进行中（未招募）
1 期
Phase 3 Study of Pembrolizumab with and without Epacadostat as a second treatment after a platinum containing chemotherapy for recurring or metastatic bladder cancerRecurrent or Progressive Metastatic Urothelial Carcinoma in Patients who have Failed a First-Line Platinum-containing Chemotherapy Regimen for Advanced/Metastatic DiseaseMedDRA version: 20.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 100000004864EUCTR2017-002310-31-GBIncyte Corporation648
进行中（未招募）
1 期
Phase 3 Study of Pembrolizumab with and without Epacadostat as a second treatment after a platinum containing chemotherapy for recurring or metastatic bladder cancerEUCTR2017-002310-31-NLIncyte Corporation85
进行中（未招募）
1 期
Phase 3 Study of Pembrolizumab with and without Epacadostat as a second treatment after a platinum containing chemotherapy for recurring or metastatic bladder cancerRecurrent or Progressive Metastatic Urothelial Carcinoma in Patients who have Failed a First-Line Platinum-containing Chemotherapy Regimen for Advanced/Metastatic DiseaseMedDRA version: 20.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 100000004864EUCTR2017-002310-31-FRIncyte Corporation648